Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 15/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991400 | 0.87 | EPHX2 (0.41) | TRPV4AKR1C3HSD11B1 | |
| SCHEMBL4986044 | 0.85 | FAAH (0.39) | — | |
| SCHEMBL4988779 | 0.84 | TDP1 (0.45) | CYP3A4AKR1C3AKR1C1HSD11B1 | |
| SCHEMBL4992135 | 0.83 | ATM (0.41) | — | |
| SCHEMBL4986058 | 0.83 | USP2 (0.46) | — | |
| SCHEMBL4989307 | 0.81 | ALDH1A1 (0.46) | AKR1C3AKR1C1HSD11B1 | |
| SCHEMBL4992334 | 0.80 | CNR1 (0.41) | AKR1C3AKR1C1 | |
| SCHEMBL4989326 | 0.80 | ALDH1A1 (0.38) | AKR1C3AKR1C1 | |
| SCHEMBL5142388 | 0.80 | TRPV4 (0.43) | TRPV4TRPM8CYP3A4KCNH2CYP19A1 | |
| SCHEMBL4989380 | 0.79 | ALDH1A1 (0.39) | AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | TRPV4 27/4885TRPM8 50/4885CYP3A4 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.